– Potential first approval of a menin inhibitor for the treatment of adult patients with relapsed or refractory AML with an NPM1 mutation – SAN DIEGO and TOKYO, June 01, 2025 (GLOBE NEWSWIRE) -- Kura ...
– 86% (32/37) CRc and 73% (27/37) CR in newly diagnosed NPM1-m AML, with 68% (17/25) of CRc responders achieving molecular MRD negativity by central NGS – Median duration of complete response and ...
Discover why Syndax Pharmaceuticals (SNDX) is a strong buy, with FDA approvals, sales set to double by 2026, and major long-term growth potential.
– Encouraging clinical activity with deep responses demonstrated in the KOMET-007 trial with the combination of 600 mg ziftomenib with 7+3 in newly diagnosed patients with NPM1-m and KMT2A-r AML – – ...
2don MSN
Breast cancer drug boosts leukemia treatment: Unexpected duo shows promise in overcoming resistance
A research team at Oregon Health & Science University has discovered a promising new drug combination that may help people ...
Kura Oncology And Kyowa Kirin Report Combination Data For KOMZIFTITM (Ziftomenib) With Venetoclax And Azacitidine In Newly Diagnosed And Relapsed/Refractory AML. – 86% (32/37) CRc and 73% (27/37) CR ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback